Risk of Hematologic Malignancies After Radioactive Iodine Treatment of Thyroid Cancer: An Unjustified Warning
- 20 June 2018
- journal article
- letter
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 36 (18), 1881-1882
- https://doi.org/10.1200/jco.2018.78.1096
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid CancerJournal of Clinical Oncology, 2018
- Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodineLeukemia, 2017
- TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic DiseaseJournal of Clinical Endocrinology & Metabolism, 2017
- Incidences and outcomes of therapy-related chronic myeloid leukemia in the era of tyrosine kinase inhibitors: Surveillance of the CML Cooperative Study GroupLeukemia Research, 2017
- Incidence of Nonthyroidal Primary Malignancy and the Association with 131I Treatment in Patients with Differentiated Thyroid CancerThyroid®, 2016
- Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer.Journal of Clinical Endocrinology & Metabolism, 2015
- Molecular Pathways: Targeting NRAS in Melanoma and Acute Myelogenous LeukemiaClinical Cancer Research, 2014
- Bone metastases of differentiated thyroid cancer: impact of early 131I-based detection on outcomeEndocrine-Related Cancer, 2007
- Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine TherapyJournal of Clinical Endocrinology & Metabolism, 2006
- Leukaemias and cancers following iodine-131 administration for thyroid cancerBritish Journal of Cancer, 1997